Yuki Kojima

8PUBLICATIONS
40CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersMolecular targetsMedical mycology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Aug 22, 2024
A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer.

Emi Noguchi, Takashi Yamanaka, Hirofumi Mukai

|Aug 14, 2024
Clinicopathological and prognostic features of HER2-null and HER2-low advanced breast cancer treated with eribulin or capecitabine.

Rui Kitadai, Tatsunori Shimoi, Shu Yazaki

|Jun 27, 2024
Immunohistochemical Profiling of SSTR2 and HIF-2α with the Tumor Microenvironment in Pheochromocytoma and Paraganglioma.

Masaki Uchihara, Akiyo Tanabe, Yuki Kojima

|Jun 28, 2023
Development of a Detection System for ESR1 Mutations in Circulating Tumour DNA Using PNA-LNA-Mediated PCR Clamping.

Yuki Kojima, Emi Noguchi, Tomomi Yoshino

|Jun 27, 2023
Clinical Activity and Exploratory Resistance Mechanism of Milademetan, an MDM2 Inhibitor, in Intimal Sarcoma with MDM2 Amplification: An Open-Label Phase Ib/II Study.

Takafumi Koyama, Toshio Shimizu, Yuki Kojima

|Nov 26, 2022
High mesothelin expression is correlated with non-squamous cell histology and poor survival in cervical cancer: a retrospective study.

Shigemasa Takamizawa, Shu Yazaki, Yuki Kojima

Pageof 2

Frequent Collaborators

5 joint publications

Kan Yonemori

4 joint publications

Tatsunori Shimoi

3 joint publications

Tadaaki Nishikawa

3 joint publications

Kazuki Sudo